Asterias Biotherapeutics Inc buy melinda
Start price
18.09.18
/
50%
€1.14
Target price
22.10.18
€1.55
Performance (%)
-32.98%
End price
22.10.18
€0.76
Summary
This prediction ended on 22.10.18 with a price of €0.76. Massive losses of -32.98% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Asterias Biotherapeutics Inc | - | - | - | - |
| iShares Core DAX® | -1.816% | -2.419% | 12.070% | 14.356% |
| iShares Nasdaq 100 | 4.333% | 8.073% | 32.493% | 59.393% |
| iShares Nikkei 225® | 0.657% | 1.234% | 2.682% | 5.342% |
| iShares S&P 500 | 2.968% | 4.613% | 26.496% | 49.719% |
Comments by melinda for this prediction
In the thread Asterias Biotherapeutics Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 12/11 Publication de résultats
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine.
The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology.
Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer.
The company was founded on September 24, 2012 and is headquartered in Fremont, CA.
Nombre d'employés
: 31 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Asterias Biotherapeutics Inc
Asterias Biotherapeutics Inc
Start price
Target price
Perf. (%)
€2.73
07.04.17
07.04.17
€3.50
26.04.17
26.04.17
23.12%
26.04.17
26.04.17
Asterias Biotherapeutics Inc
Start price
Target price
Perf. (%)
€3.07
25.05.16
25.05.16
€3.50
12.09.16
12.09.16
14.19%
12.09.16
12.09.16